CRISPR Focused Intellia Therapeutics Adds Scientific Advisors in Immuno-Oncology and Autoimmunity

CRISPR Focused Intellia Therapeutics Adds Scientific Advisors in Immuno-Oncology and Autoimmunity

Source: 
CP Wire
snippet: 

Intellia Therapeutics, Inc. (NASDAQ:NTLA),  announced on 5/14/18 the addition of new scientific advisors in immuno-oncology and autoimmunity. The advisors hail from prestigious international institutions and collectively have both scientific and clinical expertise in cell therapies in these areas.